Registered title, quoted from ClinicalTrials.gov
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Henan Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07334431, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
Inclusion criterion 3
Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
Exclusion criterion 3
Poorly controlled diabetes mellitus was present before enrollment (fasting glucose concentration ≥CTCAE level 2 after formal treatment);
Exclusion criterion 14
Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity;
Exclusion criterion 20
Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before enrollment;
Exclusion criterion 22
Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
Inclusion criterion 6
Absolute neutrophil count ≥1.5×109/L;
Inclusion criterion 10
Platelet ≥100×109 /L;
Inclusion criterion 11
Hemoglobin ≥90g/L;
Inclusion criterion 12
Total bilirubin < 1.5 ULN;
Inclusion criterion 13
ALT and/or AST < 1.5 ULN ;
Inclusion criterion 14
Serum creatinine (Cr) <1.5×ULN;
Inclusion criterion 15
Endogenous creatinine clearance ≥50ml/min;
Inclusion criterion 16
International Standardized Ratio (INR) >1.5 or partially activated prothrombin time (APTT) >1.5×ULN;
Exclusion criterion 11
At least one measurable lesion according to RECIST version 1.1;
Inclusion criterion 8
Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
Exclusion criterion 21
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07334431, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Have fully understood the study and voluntarily signed the informed consent;
- 18-75 years old (including 18 and 75 years old);
- Pathologically determined advanced gastric or gastroesophageal junction adenocarcinoma;
- No previous anti-tumor treatment for metastatic diseases;
- HER2 positive;
- Eastern Cooperation Oncology Group (ECOG) performance status of 0-1;
- Life expectancy ≥ 3 months;
- At least one measurable lesion according to RECIST version 1.1;
- The functions of vital organs met the following requirements (Blood components and cell growth factors were not allowed within 14 days before enrollment):
- Absolute neutrophil count ≥1.5×109/L;
- Platelet ≥100×109 /L;
- Hemoglobin ≥90g/L;
- Total bilirubin < 1.5 ULN;
- ALT and/or AST < 1.5 ULN ;
- Serum creatinine (Cr) <1.5×ULN;
- Endogenous creatinine clearance ≥50ml/min;
- Female patients of childbearing age should take effective contraceptive measures;
- Good compliance, cooperate with follow-up.
Exclusion Criteria:
- Failure to comply with the study protocol or study procedure;
- Previous treatment with vascular endothelial growth factor receptor (VEGFR) inhibitors, chemotherapy or immune checkpoint inhibitors;
- Have had other malignancies within the past 5 years, except basal cell or squamous cell carcinoma of the skin after radical surgery, or carcinoma in situ of the cervix;
- Known presence of symptomatic central nervous system metastasis or brain metastases;
- Had autoimmune disease or history of autoimmune disease within 4 weeks before enrollment;
- Previously received allogeneic bone marrow transplantation or organ transplantation;
- Uncontrolled malignant ascites (defined as ascites that cannot be controlled by diuretics or puncture as determined by the researcher);
- Severe cardiovascular disease, including unstable angina pectoris or myocardial infarction, occurs within 6 months before the start of study treatment;
- Subjects who are allergic to the investigational drug or any of its adjuncts;
- Participated in other domestic unapproved or unmarketed drug clinical trials and accepted the corresponding experimental drug treatment within 4 weeks before enrollment;
- International Standardized Ratio (INR) >1.5 or partially activated prothrombin time (APTT) >1.5×ULN;
- The investigator identified clinically significant electrolyte abnormalities;
- Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg;
- Poorly controlled diabetes mellitus was present before enrollment (fasting glucose concentration ≥CTCAE level 2 after formal treatment);
- Had any disease or condition prior to enrollment that affected drug absorption, or the patient could not take fruquintinib orally;
- Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unresectosed tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment;
- Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months >30 mL, hematemesis, stool, stool blood), hemoptysis (within 4 weeks >5 mL of fresh blood) or had a thromboembolic event (including stroke events and/or transient ischemic attacks) within 12 months;
- Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) <50%;
- Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure >Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) >50%;
- Unmitigated toxicity higher than CTCAE v5.0 grade 1 due to any previous anticancer therapy, excluding alopecia, lymphocytopenia, and oxaliplatin grade ≤2 neurotoxicity;
- Women who are pregnant (positive pregnancy test before medication) or breastfeeding;
- Received blood transfusion therapy, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF), within 14 days before enrollment;
- Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk;
- Urine routine indicated urinary protein ≥2+, and 24-hour urinary protein volume > 1.0g;
- Complications require long-term treatment with immunosuppressants or systemic or local use of immunosuppressive corticosteroids (> 10mg/ day prednisone or other therapeutic hormone);
- Investigators believe that the patient has any other conditions that are not suitable for participating in the study.
Quoted from ClinicalTrials.gov, NCT07334431, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07334431, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.